
New4med commenced European market launch of its novel Basivertebral Nerve Ablation (BVNA) therapy.
BVNA is a treatment for vertebrogenic pain, a type of chronic low back pain associated with bony lesions on the vertebral endplates. The system, approved in Europe, is a minimally invasive, implant-free procedure that can be performed on both inpatient and outpatient bases. It uses targeted radiofrequency energy to block the Nervus basivertebralis from transmitting pain signals to the brain, aiming to improve function and provide sustainable relief.
“By offering BVNA to physicians, we are providing access to this unique treatment for people with vertebrogenic pain in Europe for the first time,” said Daniel Seifert, designated CEO of New4med. “Our goal is to make this high-growth therapeutic option available to a broad population of people with chronic low back pain.”
Source: New4med
New4med commenced European market launch of its novel Basivertebral Nerve Ablation (BVNA) therapy.
BVNA is a treatment for vertebrogenic pain, a type of chronic low back pain associated with bony lesions on the vertebral endplates. The system, approved in Europe, is a minimally invasive, implant-free procedure that can be performed on both...
New4med commenced European market launch of its novel Basivertebral Nerve Ablation (BVNA) therapy.
BVNA is a treatment for vertebrogenic pain, a type of chronic low back pain associated with bony lesions on the vertebral endplates. The system, approved in Europe, is a minimally invasive, implant-free procedure that can be performed on both inpatient and outpatient bases. It uses targeted radiofrequency energy to block the Nervus basivertebralis from transmitting pain signals to the brain, aiming to improve function and provide sustainable relief.
“By offering BVNA to physicians, we are providing access to this unique treatment for people with vertebrogenic pain in Europe for the first time,” said Daniel Seifert, designated CEO of New4med. “Our goal is to make this high-growth therapeutic option available to a broad population of people with chronic low back pain.”
Source: New4med
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.





